富血小板血浆治疗勃起功能障碍:一项前瞻性、随机、双盲、安慰剂对照临床试验
这项前瞻性随机双盲安慰剂对照试验将61例轻中度勃起功能障碍(国际勃起功能指数评分11-25)男性随机分为富血小板血浆组(28例)和安慰剂组(33例),间隔1个月接受2次注射。第二次注射后1个月达到最小临床重要差异的比例两组无差异(富血小板血浆组14例58.3% vs 安慰剂组15例53.6%,P=.730),作者结论认为海绵体内注射富血小板血浆安全但疗效与安慰剂无差异。
要点
- 轻中度勃起功能障碍男性间隔1个月接受2次海绵体内注射富血小板血浆或安慰剂。
- 第二次注射后1个月达到最小临床重要差异的比例两组无显著差异(P=.730)。
- 两组均无重大不良事件,每组各1例轻微不良事件。
核心结论
- 作者结论认为,对轻中度勃起功能障碍男性间隔1个月给予2次海绵体内注射富血小板血浆是安全的,但富血小板血浆与安慰剂之间未发现疗效差异。
研究设计与样本
- 前瞻性、随机、双盲、安慰剂对照临床试验,纳入国际勃起功能指数评分11-25的轻中度勃起功能障碍男性,随机分为富血小板血浆组(28例)和安慰剂组(33例),共61例,两组均间隔1个月接受2次注射。
主要发现
- 第二次注射后1个月达到最小临床重要差异的比例:富血小板血浆组14例(58.3%) vs 安慰剂组15例(53.6%),P=.730。
- 富血小板血浆组国际勃起功能指数-勃起功能域均值从17.4(95%CI 15.8-19.0)变为1个月时的21(17.9-24.0);安慰剂组从18.6(95%CI 17.3-19.8)变为21.6(19.1-24.1);组间无显著差异(P=.756)。
- 两组均无重大不良事件,每组各发生1例轻微不良事件。
- 阴茎多普勒参数从基线至6个月无变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed the safety and efficacy of 2 injections of platelet-rich plasma for treating mild to moderate erectile dysfunction by conducting a prospective, randomized, double-blind, placebo-controlled clinical trial. MATERIALS AND METHODS: Men with mild to moderate erectile dysfunction (International Index of Erectile Function scores 11-25) were randomized to receive either 2 injections of platelet-rich plasma or placebo separated by 1 month. Primary outcome was percentage of men meeting minimum clinically important difference at 1 month after the second injection. Secondary outcomes were change in International Index of Erectile Function at 1, 3, and 6 months, and changes in penile vascular parameters and adverse events at 6 months. RESULTS: We randomized 61 men: 28 into platelet-rich plasma and 33 into placebo. There was no difference between groups in percentage of men meeting minimum clinically important difference at 1 month: 14 (58.3%) in platelet-rich plasma vs 15 (53.6%) in placebo (P = .730). Mean International Index of Erectile Function-Erectile Function domain changed from 17.4 (95% CI 15.8-19.0) to 21 (17.9-24.0) at 1 month in men receiving platelet-rich plasma, vs 18.6 (17.3-19.8) to 21.6 (19.1-24.1) in the placebo group; however, there was no significant difference between groups (P = .756). There were no major adverse events and only 1 minor adverse event in each group. There were no changes in penile Doppler parameters from baseline to 6 months. CONCLUSIONS: The results of our prospective, double-blind, randomized, placebo-controlled clinical trial suggest that 2 injections of intracavernosal platelet-rich plasma separated by 1 month in men with mild to moderate erectile dysfunction is safe, but we found no difference in efficacy between platelet-rich plasma and placebo.
引用
- Masterson TA, Molina M, Ledesma B, et al. Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial. J Urol. 2023. PMID: 37120727. doi:10.1097/JU.0000000000003481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。